AI updates. A diffusion-based generative model to design regulatory DNA sequences with specific activity levels. And FAbCon predicts “antigen binding and can also be used to design new antibodies with good predicted developability potential.”
Rational design of a bacterial import system for new-to-nature molecules. Clever. Many molecules can’t be “taken up” by microbes, because they don’t pass through the membrane and there are no transporters that recognize them. This paper shows that you can fuse these “non-accessible” molecules to sulfonates that are taken up by a transporter protein, called SsuABC, and thus sneak them into the cell.
Joining a cancer trial doesn’t improve survival odds. “Researchers analyzed 39 publications that compared people in cancer trials with patients who were not enrolled and found participants had no advantage when it came to survival.” And the original study.
More good news for semaglutide. In patients with type 2 diabetes and chronic kidney disease, those assigned to semaglutide (n=1767) vs. placebo (n=1766) had 18% lower risk of major cardiovascular events, 24% lower risk of a primary-outcome event.
Positive microscopy developments. Including an image sensor with 2-3 fold higher signal-to-noise ratio compared to a CMOS camera. And a new microscopy technique “enables high-fidelity, high-speed, three-dimensional (3D) imaging at near-diffraction-limit resolution.” Might I suggest Videos 2 and 5?
Discussion about this post
No posts